ATE451113T1 - Verwendung von g-csf zur hemmung der gvhd - Google Patents

Verwendung von g-csf zur hemmung der gvhd

Info

Publication number
ATE451113T1
ATE451113T1 AT00969939T AT00969939T ATE451113T1 AT E451113 T1 ATE451113 T1 AT E451113T1 AT 00969939 T AT00969939 T AT 00969939T AT 00969939 T AT00969939 T AT 00969939T AT E451113 T1 ATE451113 T1 AT E451113T1
Authority
AT
Austria
Prior art keywords
csf
gvhd
stem cells
peripheral blood
blood stem
Prior art date
Application number
AT00969939T
Other languages
English (en)
Inventor
Motoyuki Kataoka
Kaname Yamamoto
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE451113T1 publication Critical patent/ATE451113T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
AT00969939T 1999-10-20 2000-10-20 Verwendung von g-csf zur hemmung der gvhd ATE451113T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29802799 1999-10-20
PCT/JP2000/007320 WO2001028581A1 (fr) 1999-10-20 2000-10-20 Compositions medicinales pouvant inhiber gvhd

Publications (1)

Publication Number Publication Date
ATE451113T1 true ATE451113T1 (de) 2009-12-15

Family

ID=17854176

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00969939T ATE451113T1 (de) 1999-10-20 2000-10-20 Verwendung von g-csf zur hemmung der gvhd

Country Status (7)

Country Link
US (1) US8048855B1 (de)
EP (1) EP1226828B1 (de)
JP (1) JP4684513B2 (de)
AT (1) ATE451113T1 (de)
AU (1) AU7952200A (de)
DE (1) DE60043511D1 (de)
WO (1) WO2001028581A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10660920B2 (en) * 2013-03-15 2020-05-26 Tigenix Nv Lymphocyte biomarkers for determining the clinical response to cell therapy
CN112156110B (zh) * 2020-09-15 2022-10-14 上海交通大学医学院 Cd8+抑制性t细胞在免疫调节中的应用及诱导方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107483A0 (en) * 1993-11-03 1994-02-27 Yeda Res & Dev Bone marrow transplantation
US5800539A (en) * 1995-11-08 1998-09-01 Emory University Method of allogeneic hematopoietic stem cell transplantation without graft failure or graft vs. host disease
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US5880090A (en) * 1997-09-19 1999-03-09 The Hope Heart Institute Treatment of vascular graft implants with G-CSF

Also Published As

Publication number Publication date
US8048855B1 (en) 2011-11-01
DE60043511D1 (de) 2010-01-21
EP1226828A1 (de) 2002-07-31
WO2001028581A1 (fr) 2001-04-26
AU7952200A (en) 2001-04-30
EP1226828A4 (de) 2004-12-22
JP4684513B2 (ja) 2011-05-18
EP1226828B1 (de) 2009-12-09

Similar Documents

Publication Publication Date Title
MA56661B1 (fr) Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide
EA200600076A1 (ru) Композиции и способы увеличения активности теломеразы
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
EA201270615A1 (ru) Противогрибковый препарат, содержащий грибковый организм
EA200801492A1 (ru) Фармацевтическое применение замещенных амидов
ECSP077387A (es) Composiciones que contienen piperacilina, tazobactam y un ácido aminocarboxílico en un diluyente de lactato de sodio
NO20022442L (no) Legemidler for sykdommer i forbindelse med reduksjon i benmasse
DE60022683D1 (de) Nervenschutzmittel
DK0969843T3 (da) Antitussive formuleringer indeholdende theobromin
ATE383854T1 (de) Kombination ausgewählter opioide mit muscarin- antagonisten zur therapie der harninkontinenz
EP1852114A4 (de) Zusammensetzung mit dihomo-(gamma)-linolensäure (dgla) als aktivem inhaltsstoff
IL153288A0 (en) Use of growth hormone or a derivative thereof in the preparation of a medicament for hematopoiesis
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
HUP9801924A2 (hu) Nátrium/hidrogén-csere inhibitorokat és szív- és keringési zavarok kezelésére alkalmas hatóanyagokat tartalmazó gyógyszerkészítmény
BR112012016128A2 (pt) agente terapêutico (y-39983) para disfunção endotelial da córnea
BRPI0407178A (pt) Composição farmacêutica osteogênica
ATE451113T1 (de) Verwendung von g-csf zur hemmung der gvhd
ES2124861T3 (es) Derivados de aminoacidos y su utilizacion como inhibidores de la encefalinasa.
ATE404192T1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
DE60305534D1 (de) Verwendung von docosahexaensäure als wirkstoff bei der behandlung von lipodystrophie
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
SE0100873D0 (sv) Method of treatment
RU2010144554A (ru) Средство для предотвращения и/или лечения сосудистых заболеваний
WO2006020912A3 (en) Treatments for congestive heart failure

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties